Targeted immunomodulation with CD44-targeting nanovaccine enhances antitumor immunity in melanoma through TLR7/8 and TLR3 agonists
Biomaterials Science · 2026
DOI: 10.1039/d6bm01033d ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomaterials Science, 2026. Verfasst von Shameer Pillarisetti und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Chonnam National University Medical School, 264 Seoyang-ro, Hwasun, Jeollanam-do 58128, Republic of Korea. pik96@j…. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Toll-Like Receptor 3, Toll-Like Receptor 8, Hyaluronan Receptors. Die Arbeit nennt 25 Literaturangaben. Gefördert von: National Research Foundation of Korea, Chonnam National University Hwasun Hospital.
Abstract (Originalsprache)
Schematic illustration of a CD44-targeting nanovaccine utilizing dual TLR7/8 and TLR3 agonists to drive targeted immunomodulation and overcome immune evasion in melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Chonnam National University Medical School, 264 Seoyang-ro, Hwasun, Jeollanam-do 58128, Republic of Korea. pik96@jnu.ac.kr.
- Department of Pharmacy, University of Chieti - Pescara "G. d'Annunzio", Via dei Vestini 31, 66100, Chieti, Italy.
- Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, 322 Seoyang-ro, Hwasun, Jeollanam-do 58128, Korea.
- Department of Polymer Science and Engineering, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon, 34134, Republic of Korea.
- NanoLife Innovations Laboratory, Smart Materials and Devices Division, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka, India. sajiuthaman@gmail.com.
- DRCure Inc, Hwasun, 58128, Republic of Korea.
Förderung
- National Research Foundation of Korea
- Chonnam National University Hwasun Hospital
Zitieren
APA
Pillarisetti, S., Sathiyamoorthy, P., Jung, T. Y., Uthaman, S., & Park, I. K. (2026). Targeted immunomodulation with CD44-targeting nanovaccine enhances antitumor immunity in melanoma through TLR7/8 and TLR3 agonists. Biomaterials Science. https://doi.org/10.1039/d6bm01033d
Vancouver
Pillarisetti S, Sathiyamoorthy P, Jung TY, Uthaman S, Park IK. Targeted immunomodulation with CD44-targeting nanovaccine enhances antitumor immunity in melanoma through TLR7/8 and TLR3 agonists. Biomaterials Science. 2026. doi:10.1039/d6bm01033d
BibTeX
@article{Pillarisetti2026,
author = {Pillarisetti, Shameer and Sathiyamoorthy, Padmanaban and Jung, Tae-Young and Uthaman, Saji and Park, In-Kyu},
title = {Targeted immunomodulation with CD44-targeting nanovaccine enhances antitumor immunity in melanoma through TLR7/8 and TLR3 agonists},
journal = {Biomaterials Science},
year = {2026},
doi = {10.1039/d6bm01033d}
}
EUVIMED